Tindazole (Tinidazole)
Brand Names: Tindazole
Methodology & AI Transparency ⓘ
Tindazole (Tinidazole) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary nitroimidazole antimicrobial presentation registered by REMEDYREPACK INC., Tindazole supplies active moiety Tinidazole (cross-referenced at /meds/tinidazole) in 250 mg/1 Tablet, Film Coated; 500 mg/1 Tablet, Film Coated (NDC 70518-4172, 64980-426; SPL 2026-08-18).
- 2 Real-world patient consensus: Registered under RxNorm 199519-B705184172 and SPL 2026-08-18, pairing Tindazole packaging with active ingredient Tinidazole.
- 3 Typical cash cost range: Public pharmacy ledger: $98.68 low cash benchmark vs. $261.50 chain retail average ($1.2526/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Tindazole (Tinidazole)): nausea (10.8%), headache (9.4%), dizziness (8.7%).
Ask our AI Specialists anything about Tindazole (Tinidazole)
Tindazole (Tinidazole) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary nitroimidazole antimicrobial presentation registered by REMEDYREPACK INC., Tindazole supplies active moiety Tinidazole (cross-referenced at /meds/tinidazole) in 250 mg/1 Tablet, Film Coated; 500 mg/1 Tablet, Film Coated (NDC 70518-4172, 64980-426; SPL 2026-08-18). Clinical prescribing and dispensing guidelines focus on Tinidazole Tablet is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3.
The active constituent inside Tindazole—Tinidazole—functions as a targeted nitroimidazole antimicrobial agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Tinidazole, Tindazole (registered by REMEDYREPACK INC., SPL 2026-08-18) specifies proprietary packaging (70518-4172, 64980-426) and 250 mg/1 Tablet, Film Coated; 500 mg/1 Tablet, Film Coated quality controls alongside a $1.2526/unit NADAC acquisition baseline.
Systemic exposure to Tindazole (Tinidazole) reflects Estimated 45%–57% oral systemic absorption for Tindazole (Tinidazole) absorption kinetics and phase i/ii hepatic conjugation of tindazole (tinidazole) coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 3–7 hours terminal plasma half-life for Tindazole (Tinidazole) half-life window (peak plasma concentration (tmax) reached 1–3 hours post-dose for tindazole (tinidazole) response profile).
Dosing protocols (250 mg/1 Tablet, Film Coated or 500 mg/1 Tablet, Film Coated or 250mg Tablet or 500mg Tablet) balance efficacy (74.00% patient satisfaction across 5 logs) against nausea (10.8% of reports), headache (9.4% of reports), dizziness (8.7% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving tinidazole (nitroimidazole antimicrobial); concurrent restricted medications flagged in section 4/7 of the tindazole (tinidazole) dailymed monograph (199519-b705184172).
Concurrent Tindazole (Tinidazole) exposure alters anticoagulant pharmacodynamics, requiring closer hemorrhagic surveillance.
Assess baseline hepatic panels and interacting prescriptions when starting Tindazole (Tinidazole) (nitroimidazole antimicrobial).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Tinidazole (nitroimidazole antimicrobial)
- Concurrent restricted medications flagged in Section 4/7 of the Tindazole (Tinidazole) DailyMed monograph (199519-B705184172)
Logged Side-Effect Incidence (5 Reports)
Tindazole (Tinidazole) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tindazole (Tinidazole))
Human clinical trial evidence for Tindazole (Tinidazole) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Tindazole (Tinidazole) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.2526/unit (~$37.58/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $261.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $98.68 / mo | View logs ↓ |
Tindazole (Tinidazole) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tindazole (Tinidazole) RxNorm Concept ID | 199519-B705184172 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.2526 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $261.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $98.68 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 74.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tindazole (Tinidazole) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Tindazole (Tinidazole): FDA labeling (2026-08-18, NDC 70518-4172), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tindazole (Tinidazole) community threads and patient logs by age, biological sex, dosage, and treatment duration.